<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03637335</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-A-2014-11</org_study_id>
    <nct_id>NCT03637335</nct_id>
  </id_info>
  <brief_title>Comparing Palliative Radiotherapy With or Without Carboplatin</brief_title>
  <acronym>METAXIOM</acronym>
  <official_title>Phase-3 Study, Randomized, Controlled, Multi-center, Double Blind, Comparing Palliative Radiotherapy With or Without Carboplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study population has locally advanced or metastatic bronchial or head and neck cancer.

      This study assesses the value of concomitant chemo/radiotherapy with carboplatin daily during
      metastatic radiotherapy versus radiotherapy alone.

      The realization of a systemic treatment during the radiotherapy could make it possible to
      obtain a benefit on the control of the evolution of the metastases and thus of the pains
      generated, as well as on the quality of life of the patients. In addition, a benefit in
      overall survival is possible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population has locally advanced or metastatic bronchial or head and neck cancer.

      Patients receive 10 injections of carboplatin (validated chemo-sensitizing molecule) or
      placebo (glucose) before 10 radiation sessions.

      The overall duration is 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped due to insufficient recruitment.
  </why_stopped>
  <start_date type="Actual">August 17, 2015</start_date>
  <completion_date type="Actual">May 28, 2018</completion_date>
  <primary_completion_date type="Actual">November 28, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase-3 study, randomized, controlled, multi-center, double blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local progression-free survival of chemo radiotherapy compared with placebo-associated radiotherapy</measure>
    <time_frame>36 months</time_frame>
    <description>= delay between the start date of treatment and the date of the first event related to the treated location</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact in quality of life</measure>
    <time_frame>25 months</time_frame>
    <description>Evaluate with questionnaire QLQ-C30 at inclusion, at the end of treatment and during the following</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in intensity of pain</measure>
    <time_frame>25 months</time_frame>
    <description>Analogical visual scale (EVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of dose of pain medication</measure>
    <time_frame>25 months</time_frame>
    <description>variation of dosage of pain medication between inclusion and the end of radiotherapy (mg, number of caps, ...)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity due to radiotherapy</measure>
    <time_frame>25 months</time_frame>
    <description>Toxicity 4 weeks after radiotherapy with NCI-CTC-AE v4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survey</measure>
    <time_frame>36 months</time_frame>
    <description>Time between inclusion and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate free progression survival</measure>
    <time_frame>36 months</time_frame>
    <description>Time between inclusion and first progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>irradiation + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Carboplatin. :10 injections 1h prior irradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>irradiation + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Placebo :10 injections 1h prior irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>irradiation + carboplatin</intervention_name>
    <description>30 Gy en 10 fractions de 3 Gy + 10 injections of carboplatin</description>
    <arm_group_label>irradiation + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>irradiation + placebo</intervention_name>
    <description>30 Gy en 10 fractions de 3 Gy + 10 injections of placebo</description>
    <arm_group_label>irradiation + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with locally advanced or metastatic bronchial or head and neck cancer

          -  Patient require palliative radiotherapy

          -  Age ≥ 18 years

          -  PS ≤ 2

          -  Obtaining the signed written consent of the patient

          -  Patient affiliated to a social security scheme

        Exclusion Criteria:

          -  Other chemotherapy or targeted therapy

          -  Prior radiation

          -  Patients with thrombopenia &lt; 100 000

          -  Patients with neutropenia &lt; 2000

          -  Patients with renal clearance &lt; 20 mL/min

          -  Known hypersensitivity to platinum salt

          -  Treatment with phenytoin or fosphenytoin

          -  In previous three months, a vaccination against yellow fever, live vaccin or live
             attenuated vaccine

          -  Unchecked diabetes

          -  hemorrhagic tumor

          -  Refusal of participation or inability to issue informed consent

          -  Person deprived of liberty or adult under guardianship

          -  Minor patients, pregnant or lactating women

          -  Participation in other interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FABRICE DENIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Bernard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fabrice Denis</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>irradiation</keyword>
  <keyword>placebo</keyword>
  <keyword>carboplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

